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Abstract
An accurate knowledge of the epidemiology of community-acquired pneumonia (CAP) is key for selecting appropriate antimi-
crobial treatments. Very few etiological studies assessed the appropriateness of empiric guideline recommendations at a multi-
national level. This study aims at the following: (i) describing the bacterial etiologic distribution of CAP and (ii) assessing the
appropriateness of the empirical treatment recommendations by clinical practice guidelines (CPGs) for CAP in light of the
bacterial pathogens diagnosed as causative agents of CAP. Secondary analysis of the GLIMP, a point-prevalence international
study which enrolled adults hospitalized with CAP in 2015. The analysis was limited to immunocompetent patients tested for
bacterial CAP agents within 24 h of admission. The CAP CPGs evaluated included the following: the 2007 and 2019 American
Thoracic Society/Infectious Diseases Society of America (ATS/IDSA), the European Respiratory Society (ERS), and selected
country-specific CPGs. Among 2564 patients enrolled, 35.3% had an identifiable pathogen. Streptococcus pneumoniae (8.2%)
was the most frequently identified pathogen, followed by Pseudomonas aeruginosa (4.1%) and Klebsiella pneumoniae (3.4%).
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CPGs appropriately recommend covering more than 90% of all the potential pathogens causing CAP, with the exception of
patients enrolled fromGermany, Pakistan, and Croatia. The 2019 ATS/IDSA CPGs appropriately recommend covering 93.6% of
the cases compared with 90.3% of the ERS CPGs (p < 0.01). S. pneumoniae remains the most common pathogen in patients
hospitalized with CAP. Multinational CPG recommendations for patients with CAP seem to appropriately cover the most
common pathogens and should be strongly encouraged for the management of CAP patients.
Keywords Community-acquired pneumonia . Antimicrobial treatment . Guidelines . Streptococcus pneumoniae
Introduction
Community-acquired pneumonia (CAP) is a clinical and pub-
lic health issue worldwide [1]. The Global Burden of
Diseases, Injuries, and Risk Factors Study 2017 estimated that
lower respiratory infections affected approximately 471.8 mil-
lion people and caused 2.6 million deaths in 2017 [2].
The selection of an appropriate empirical antimicrobial
therapy is crucial for a successful outcome [3]. National and
international CAP guidelines provide specific recommenda-
tions based on site of care (intensive vs. non-intensive care
unit) and pathogen-related risk factors, including those for
Pseudomonas aerug inosa , me th ic i l l in - res i s t an t
Staphylococcus aureus (MRSA), and influenza viruses.
However, it is unclear if those recommendations provide ad-
equate antimicrobial coverage.
The aim of the present study was to describe the bacterial
etiology of CAP in adults hospitalized in different settings, as
well as to assess the appropriateness of the empirical treatment
recommendations issued by clinical practice guidelines
(CPGs) in relation to the bacteria detected in CAP patients.
Materials and methods
Study design, setting, and participants
We performed a secondary analysis of the Global Initiative for
MRSA Pneumonia (GLIMP) study, an international, multi-
center, point-prevalence study [4]. GLIMP was conducted
across 222 hospitals in 54 countries over 4 days, with 1 day
per month randomly selected during March, April, May, and
June 2015. All consecutive adults (≥ 18 years old) hospital-
ized for CAP at the participating centers were enrolled in the
study. The following patients were excluded from the analy-
sis: (i) immunosuppressed patients; (ii) patients not tested for
bacterial agents of CAP within 24 h of admission; (iii) patients
with a diagnosis of hospital-acquired or ventilator-associated
pneumonia. Bacterial testing within 24 h of admission includ-
ed the following: blood and respiratory cultures (e.g., sputum,
pleural fluid, endotracheal aspirate, and bronchoalveolar la-
vage), pneumococcus urinary antigen, Legionella urinary an-
tigen, serology for atypical pathogens, and lung biopsy. The
GLIMP coordinating center was located at the University of
Texas Health, San Antonio, in San Antonio, TX, USA. The
coordinating center received expedited project approval by the
institutional review board (number HSC20150184E). The re-
view board waived the need for receipt of informed consent
due to the nature of the study. A detailed description of the
GLIMP organization and methodology was previously pub-
lished [4].
Study outcomes
The primary outcome of this study was the assessment of the
appropriateness of the empirical antimicrobial treatment rec-
ommendations for CAP issued by CPGs, with particular em-
phasis on the appropriateness of country-specific CPG recom-
mendations (see definition below).
Study definitions
CAP was defined by the presence of pulmonary infiltrates on
thoracic imaging (chest radiograph, computerized tomography,
or ultrasound) during the first 48 h of hospitalization and ≥ 1 of
the following criteria: new or increased cough with or without
sputum production or with purulent respiratory secretions; fe-
ver (documented rectal or oral temperature ≥ 37.8 °C) or hypo-
thermia (documented rectal or oral temperature < 36 °C); and
evidence of systemic inflammation, such as abnormal white
blood cell count (leukocytosis [> 10,000 cells/μL], leukopenia
[< 4000 cells/μL], or bandemia [> 10%]) and increased C-
reactive protein or procalcitonin concentrations above the local
upper limit of normal. MRSA was defined according to the
Clinical and Laboratory Standards Institute (CLSI) guidelines
based on an oxacillin minimum inhibitory concentration ≥
4 μg/mL. Immunosuppression was defined by the presence of
at least one among the following conditions: (i) AIDS, defined
either as human immunodeficiency virus infection with CD4+
lymphocyte count < 200/μL or by the occurrence of an AIDS-
defining condition; (ii) aplastic anemia; (iii) asplenia; (iv) he-
matological cancer (e.g., lymphoma, acute or chronic leukemia,
or multiple myeloma); (v) chemotherapy during the last
3 months; (vi) neutropenia (neutrophil count < 500/μL); (vii)
administration of biological drugs (including trastuzumab and
therapies for autoimmune diseases, e.g., anti-tumor necrosis
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factor α, prescribed for ≥ 6 months before hospital admission);
(viii) lung transplantation; (ix) chronic steroid use (> 10mg/day
of prednisone or equivalent prescribed for ≥ 3 months before
hospital admission); (x) lung cancer either with neutropenia or
treated with chemotherapy; (xi) other solid tumors either with
neutropenia or treated with chemotherapy; (xii) other immuno-
deficiencies (including congenital/genetic immunodepression
and immunosuppressive therapy administered for hematologi-
cal cancers/solid organ transplantations other than lungs) [5].
The following CAP CPGs were evaluated: the 2007
American Thoracic Society/Infectious Diseases Society of
America (ATS/IDSA) guidelines [6], the 2019 ATS/IDSA
guidelines [7], the European Respiratory Society (ERS) guide-
lines [8], the Spanish Society of Pneumology and Thoracic
Surgery (SEPAR) guidelines [9], the Latin American
Association of the Thorax (ALAT) guidelines [10], the
Indian Chest Society and National College of Chest
Physicians (ICS/NCCP) guidelines [11], the British Thoracic
Society (BTS) guidelines [12], the guidelines issued by the
German Respiratory Society, the Paul-Ehrlich-Society for
Chemotherapy, the German Society for Infectious Diseases,
the Competence Network CAPNETZ, the Austrian
Respiratory Society, the Austrian Society for Infectious and
Tropical Diseases and the Swiss Respiratory Society [13], the
Pakistan Chest Society guidelines [14], the Portuguese
Respiratory Society guidelines [15], and the Croatian guide-
lines [16] (Table 1).
The appropriateness of the recommendations issued by the
CPGs was defined computing the concordance between the
detected pathogens and the antibiotic(s) recommended by the
CPGs. The therapy recommended by the CPGs relies on the
clinical setting and the presence of risk factors for MRSA or
P. aeruginosa. Treatment was deemed appropriate if effective
against the diagnosed pathogen (Table 1).
Statistical analysis
Continuous variables are presented as medians with interquar-
tile ranges (IQR). Categorical variables are summarized with
absolute frequencies and percentages. Comparisons between
groups were made with the chi-square or Fisher exact test, as
appropriate. A two-sided p value < 0.05 was considered statis-
tically significant. Statistical analyses were performed using the
SPSS Statistics, version 24, software (IBM, Armonk, NY, US).
Results
Among the 2564 patients (57.9% males; age, median, and
IQR: 68; 53–80 years old) included in the analysis, 494
(19.3%) were admitted in an ICU. The following bacterial
tests were performed in the study population: blood cultures
(2110; 82.3%), sputum cultures (1886; 73.6%), other
respiratory cultures (552; 21.5%), pneumococcal urinary an-
tigen (894; 34.9%), Legionella urinary antigen (899; 35.1%),
Mycoplasma pneumoniae serology (220; 8.6%), Chlamydia
pneumoniae serology (202; 7.9%), Legionella pneumophila
serology (175; 6.8%), and lung biopsy (7; 0.3%). At least
one bacterial pathogen was identified as the causative agent
of CAP in 906 (35.3%) patients. Streptococcus pneumoniae
was the most prevalent pathogen, accounting for 211 (8.2%)
cases. Pseudomonas aeruginosa and Klebsiella pneumoniae
were the second and the third most prevalent pathogens, ac-
counting for 105 (4.1%) and 87 (3.4%) cases, respectively.
MRSA was responsible for 3.0% of CAP episodes globally,
ranging from 1.2% of the cases in Portugal to 4.8% of the
cases in USA and Argentina. After the stratification of non-
ICU vs. ICU patients, S. pneumoniae, P. aeruginosa, and
K. pneumoniae continued to be the most prevalent etiologies
(Table 2). A significantly higher proportion of CAP cases was
caused by MRSA in the ICU in comparison with those man-
aged in the non-ICU setting (6.9% vs. 2.1%, p value < 0.01).
Similarly, P. aeruginosa played a more relevant role in the
ICU if compared with cases in the non-ICU setting (6.7%
vs. 3.5%; p value < 0.01).
Guideline recommendations were appropriate to cover po-
tential pathogens in approximately 90% of the cases, both in
ICU and in non-ICU patients, with the only exception of
Germany, Pakistan, and Croatia, where a slightly inferior bac-
terial coverage was reported (Table 3). When the performance
of country-specific CPGs was analyzed, a similar or slightly
inferior bacterial coverage compared with the 2007 ATS/
IDSA, 2019 ATS/IDSA, and the ERS CPG recommendations
was noted. Pakistan was the only country where nation-
specific CPGs provided in the overall population and in the
ICU population a higher empirical treatment coverage than the
ATS/IDSA and ERS CPGs (Table 3).
The 2019 ATS/IDSA treatment recommendations appro-
priately covered a wider proportion of CAP cases than the
ATS/IDSA 2007 and the ERS recommendations in the overall
study population (93.6% vs. 92.2%, p value 0.04; 93.6% vs.
90.3%, p value < 0.01). Similar results were achieved when
the non-ICU population (94.1% vs. 92.5%, p value 0.04;
94.1% vs. 90.5%, p value < 0.01) and the ICU population
were evaluated (91.9% vs. 90.9%, p value 0.57; 91.9% vs.
89.5%, p value 0.19) (Table 3).
While MRSA CAP was diagnosed in 34/494 (6.9%) ICU
cases, an anti MRSA empirical treatment was recommended
by the 2007 and 2019 ATS/IDSA recommendations in 97/494
(19.6%) and 124/494 (25.1%) CAP ICU cases, respectively.
Similarly, while P. aeruginosa CAP was diagnosed in 33/494
(6.7%) ICU patients, an anti P. aeruginosa empirical treatment
was suggested by the 2007 ATS/IDSA, the 2019 ATS/IDSA,
and the ERS recommendations in 163/494 (32.9%), in 118/
494 (23.9%), and in 180/494 (36.4%) CAP ICU cases, respec-
tively (Figs. 1 and 2).
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Discussion
The present study showed that bacterial pathogens were de-
tected in 35.3% of CAP patients tested for bacteria, with
S. pneumoniae identified in 8.2% of the cases. National and
international CPGs recommended an appropriate empirical
treatment in the vast majority (> 90%) of the patients
hospitalized with CAP, with national CPGs providing a simi-
lar or slightly inferior bacterial coverage compared with the
ATS/IDSA and ERS CPGs. The 2019 ATS/IDSA tended to
perform better than the 2007 ATS/IDSA and the ERS CPGs,
both in the non-ICU and in the ICU setting. In general, CPGs
suggested anti MRSA and anti P. aeruginosa treatments more
frequently than needed.
Table 1 Main empirical treatment recommendations by national/international clinical practice guidelines for hospitalized CAPwhether in the intensive
care unit (ICU) or in non-ICU setting
CAP clinical practice guidelines Non-ICU CAP empirical
treatment recommendations
ICU CAP empirical treatment recommendations
ATS/IDSA guidelines 2007 [6] FQ or β-lactam plus macrolide. β-lactam plus either azithromycin or a respiratory FQ. If
Pseudomonas aeruginosa risk factors, antipseudomonal
β-lactam plus FQ or antipseudomonal β-lactam plus
aminoglycoside and azithromycin or antipseudomonal
β-lactam plus aminoglycoside and FQ. If risk factors for
community-acquired Staphylococcus aureus, add
vancomycin or linezolid.
ATS/IDSA guidelines 2019 [7] FQ or β-lactam plus macrolide. If Pseudomonas
aeruginosa risk factors, antipseudomonal
β-lactam plus FQ or a macrolide. If risk
factors for community-acquired
Staphylococcus aureus, add vancomycin or
linezolid.
β-lactam plus either a macrolide or a respiratory FQ. If
Pseudomonas aeruginosa risk factors, antipseudomonal
β-lactam plus FQ or a macrolide. If risk factors for
community-acquired Staphylococcus aureus, add
vancomycin or linezolid.
ERS guidelines [8] β-lactam monotherapy or FQ or β-lactam plus
macrolide.
Non-antipseudomonal cephalosporin III plus either macrolide or
FQ. If Pseudomonas aeruginosa risk factors,
antipseudomonal β-lactam plus either FQ or aminoglycoside
and macrolide.
SEPAR guidelines [9] FQ or β-lactam plus macrolide. β-lactam plus either azithromycin or FQ. If Pseudomonas
aeruginosa risk factors, antipseudomonal β-lactam plus FQ.
If risk factors for community-acquired methicillin-resistant
Staphylococcus aureus, levofloxacin plus either vancomycin
or linezolid.
ALAT guidelines [10] FQ or β-lactam plus macrolide. Non-antipseudomonal β-lactam plus FQ. If Pseudomonas
aeruginosa risk factors, antipseudomonal β-lactam plus FQ.
ICS/NCCP guidelines [11] β-lactam plus macrolide. FQ only if β-lactam
allergy and no risk for tuberculosis.
Non-antipseudomonal β-lactam plus macrolide. If
Pseudomonas aeruginosa risk factors, antipseudomonal
β-lactam plus either macrolide or FQ. FQ can be used only if
no risk factors for tuberculosis.
BTS guidelines [12] β-lactam monotherapy or macrolide
monotherapy, if low severity CAP. If moderate
severity CAP, FQ or β-lactam plus macrolide.
β-lactam plus macrolide.
Germany guidelines [13] FQ or β-lactam plus macrolide. β-lactam plus macrolide. If influenza season, add oseltamivir. If
Pseudomonas aeruginosa risk factors, antipseudomonal
β-lactam plus either FQ or aminoglycoside.
Pakistan Chest Society
guidelines [14]
Macrolide monotherapy or FQ or β-lactam plus
macrolide. If Pseudomonas aeruginosa risk
factors, β-lactam plus either aminoglycoside
or FQ or aminoglycoside and FQ.
β-lactam plus either FQ or macrolide. If Pseudomonas
aeruginosa risk factors, β-lactam plus either aminoglycoside
or FQ or aminoglycoside and FQ. If MRSA risk factors, add
vancomycin or linezolid.
Portuguese Respiratory Society
guidelines [15]
FQ or β-lactam plus macrolide or β-lactam plus
doxycycline.
β-lactam plus either FQ or macrolide. If Pseudomonas
aeruginosa risk factors, either β-lactam plus FQ or β-lactam
plus aminoglycoside plus FQ or macrolide.
Croatian guidelines [16] β-lactam monotherapy or β-lactam plus
macrolide.
Either β-lactam plus macrolide or FQ. If Pseudomonas
aeruginosa risk factors, antipseudomonal β-lactam plus FQ.
ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America; ERS, European Respiratory Society; SEPAR, Spanish Society of
Pneumology and Thoracic Surgery; ALAT, Latin American Association of the Thorax; ICS/NCCP, Indian Chest Society and National College of
Chest Physicians; BTS, British Thoracic Society; FQ, fluoroquinolone; β-lactam, beta-lactam; CAP, community-acquired pneumonia
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The diagnostic yield of bacterial testing that we observed in
hospitalized CAP (35.3% of the patients) is consistent with
what is reported in other large studies, such as the EPIC study
[17–20]. The EPIC study, which was a prospective, multicen-
ter, population-based, active surveillance study conducted by
the USA Centers for Disease Control and Prevention (CDC)
between 2010 and 2012, enrolled 2259 adult patients
hospitalized with CAP in the USA. The authors found a path-
ogen in only 37.7% of the cases [17–20]. On the contrary, in
the Medicare administrative database, a pathogen was identi-
fied in 7.6% of the CAP cases [21]. When compared with
previous studies, the novelty of the GLIMP approach lies in
its point-prevalence design, international nature (222 centers
in 54 countries in 6 continents), and the analysis of real-life
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data. Furthermore, the GLIMP approach differs from the
Medicare database for its primary rather than administrative
data collection. Several other factors may also account for the
different results reported by the GLIMP study and the
Medicare database. The review of the Medicare database
was published in 2011 but was performed in 2009, 6 years
before the GLIMP study was performed: the microbiological
progress may partially justify this difference. Second, the
Medicare review findings may reflect the implementation of
the 2007 ATS/IDSA CAP CPGs, which discouraged any mi-
crobiological studies in most cases, and the issue of cost in the
USA health care system [22]. Third, GLIMP data were de-
rived from clinical sites, which are mostly tertiary care centers,
whereas Medicare data might have included both tertiary and
non-tertiary health care centers. Despite the variability of
study-related characteristics, the persistently low pathogen de-
tection yield highlights the suboptimal understanding of the
dynamics of CAP etiology and the weak evidence supporting
recommendations for empirical antimicrobial treatment.
Therefore, studies implementing innovative pathogen-
discovery approaches are urgently needed [22].
Our findings confirmed a substantial variability of CAP
etiology depending on the geographic region and the clinical
setting. S. pneumoniaewas the most prevalent etiology overall
both in the non-ICU and ICU settings [18, 23–25]. However,
S. pneumoniae prevalence ranged from 17.9% CAP cases in
Spain to 2.2% CAP cases in India. This substantial variability
in pneumococcal CAP cases may reflect the variability in
pneumococcal vaccination rates and serotype circulation
across regions [26, 27]. Mycobacterium tuberculosis was
found to be an important agent of CAP, mainly in India and
other Asian and African countries [28, 29].
MRSAwas detected in 3.0% of CAP cases worldwide [4].
Our secondary analysis highlighted a high prevalence of
S. aureus CAP cases in the USA, at the point that S. aureus
CAP was more frequent than S. pneumoniae CAP in the USA
(7.5% vs. 4.8% of the CAP cases in the overall population).
The unusual etiologic distribution of CAP in the USA may
result from an epidemiological shift due to the broad pneumo-
coccal vaccination coverage in the USA [26, 27]. This shift in
microbiology patterns may have important implications in the
antibiotic treatment guideline recommendations. Among
S. aureus CAP in the USA, MRSA accounted for more than
half of the cases. Similarly, Moran and collaborators detected
MRSA in 14 out of 627 (2.4%) of the patients hospitalized
with CAP in the USA [30].
The significantly higher proportions of MRSA and
P. aeruginosa CAP cases in the ICU compared with the
non-ICU landscape suggests how clinical settings can influ-
ence the etiology of CAP. Frailty of patients harboring
P. aeruginosa and severity of MRSA CAP may explain
the higher frequency of P. aeruginosa and MRSA in the
ICU [30–34]. These data strengthen the need for prompt
microbiological testing in severe CAP cases, as those man-
aged in the ICU. Furthermore, the not-infrequent occur-
rence of MRSA and P. aeruginosa CAP in the ICU calls
for the selection of empirical antimicrobials based on the
evaluation of pathogen-specific risk factors and for careful
antimicrobial stewardship approaches in the ICU.
Antimicrobial stewardship should allow a rapid de-
escalation of unnecessary antimicrobial treatments once mi-
crobiological tests are available and also an appropriate an-
timicrobial treatment duration.
Our study documented the appropriateness of empirical
treatment guideline recommendations in more than 90% of
the CAP cases evaluated, both in the non-ICU and in the
ICU setting, reinforcing the invitation to implement guideline
recommendations when treating patients with CAP.
With the sole exception of the Pakistan Chest Society
CPGs, country-specific CPGs were inferior to ATS/IDSA
and ERS CPGs in the appropriateness of empirical treatment
recommendations in the overall study population and also in
the non-ICU and in the ICU settings. Of note, when applied to
the UK CAP patients, BTS CPGs appropriately covered
89.5% of the CAP cases, while ATS/IDSA and ERS CPGs
covered more than 93% of the cases. Similarly, the perfor-
mance of ERS CPGs was inferior to the performance of the
2019ATS/IDSACPGs, even when applied to European coun-
tries, such as Spain, Italy, UK, Germany, and Croatia. The
suboptimal performance of country-specific CPGs in the epi-
demiological settings where they were meant to be applied
suggests the presence of pitfalls in these CPGs. We could
speculate that the following factors may have contributed to
the low performance of country-specific CPGs: (i) BTS CPGs
allow β-lactam monotherapy and macrolide monotherapy in
the non-ICU setting, leaving uncovered atypical agents of
CAP and several Gram-negative pathogens, respectively; (ii)
anti MRSA and anti P. aeruginosa empirical treatments are
not suggested in the ICU by the BTS CPGs; (iii) Croatian
CPGs favor β-lactam monotherapy in the non-ICU setting,
leaving uncovered atypical agents of CAP; (iv) differences
in the identification of P. aeruginosa risk factors. Similarly,
the difference between the 2019 ATS/IDSA and the ERS
CPGs may be associated with the more restrictive use of anti
MRSA coverage based on the ERS CPGs and with the more
selective anti P. aeruginosa treatment indications based on the
2019 ATS/IDSA CPGs. In addition, the ERS recommenda-
tions attempt to provide a single set of recommendations for a
large number of countries, which differ for geographic distri-
bution, ecology, and health care system (see Electronic
Supplementary Materials).
The slightly better performance of the 2019 ATS/IDSA
compared with the 2007 ATS/IDSA CPGs may result from
the more attentive selection of P. aeruginosa and MRSA risk
factors and should be carefully re-evaluated by future studies
in the upcoming years.
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Of note, we observed a significant difference between the
frequency of anti MRSA treatments recommended by the
2007 and 2019 ATS/IDSA CPGs for ICU patients (97 and
124 empirical anti MRSA treatments recommended by the
2007 and 2019 ATS/IDSA CPGs, respectively) and the fre-
quency of MRSA CAP diagnosed in the ICU (34 MRSA
CAP). Similar results were found when anti P. aeruginosa
treatment recommendations and P. aeruginosa CAP in ICU
were evaluated. The high number of anti MRSA and anti
P. aeruginosa empiric therapies recommended by the CPGs
should prompt future studies to better define local risk factors
for MRSA and P. aeruginosa, as suggested by the 2019 ATS/
IDSA CPGs. More stringent recommendations may reduce
the use of unnecessary therapies, leading to a decrease in the
rate of drug-related adverse events and of antimicrobial
resistance.
This study has several limitations. First, this is a secondary
analysis of an observational point-prevalence study that can-
not yield causal relationships. Second, the external validity of
this study is hampered by geographic and temporal constrains.
Specifically, data were mainly retrieved from tertiary care cen-
ters. Furthermore, the GLIMP study enrolled patients during
the period March–June 2015, in order to cover the end of the
winter season in the Northern Hemisphere and the start of the
winter season in the Southern Hemisphere. Studies carried out
during different seasons or the whole year may yield different
results. Finally, the results of the GLIMP study are indicative
of the testing efforts and the etiology of CAP in 2015 and
cannot be generalized to any time period before or after the
year 2015. Third, complete radiological and anamnestic infor-
mation were not included in the original GLIMP dataset, ham-
pering our ability to detect conditions at increased risk for anti
MRSA coverage (e.g., necrotizing pneumonia and previous
influenza).
In conclusion, S. pneumoniae is the most prevalent bacte-
rial pathogen in patients hospitalized with CAP. CPGs seem to
appropriately recommend to cover the most prevalent patho-
gens in different settings and should be strongly encouraged
when managing patients with CAP. Future studies should pro-
mote innovative microbiological testing for CAP and should
address the gap between the CPG recommendations and the
antibiotic prescription for patients hospitalized with CAP.
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